A Guide to Using Extended-Release Buprenorphine (Sublocade®) in Opioid Agonist Therapy (OAT)

Guidelines
by
L'Équipe de soutien clinique et organisationnel en dépendance et itinérance (ESCODI)

Release Date

2023

Geography

Canada

Language of Resource

French and English

Full Text Available

Yes

Open Access / OK to Reproduce

No

Peer Reviewed

No

Findings/Key points

The content of this guide is based on scientific data and clinical guidelines and is the result of discussions and debate by a committee of Québec-based expert practitioners. In addition, the content of the document was verified by competent experts to ensure that it was as accurate as possible in a context where there is a still a paucity of quality literature. However, it should be noted that the guide is not prescriptive in nature, and its authors cannot be held accountable for the clinical practices of professionals. Clinicians are expected to assume responsibility for being appropriately qualified and trained. They must exercise clinical judgment when providing care and services, in compliance with the professional standards and codes of ethics to which they are subject. Should there be any doubt about whether or how the molecule should be used, consulting an expert is recommended.

 

English : https://dependanceitinerance.ca/wp-content/uploads/2023/06/230612-Outil…

Keywords

Clinical guidance
Substitution/OAT